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Vernakalant Versus Amiodarone for AF Conversion January 18, 2011:313–21Randomized Active-Controlled Study Comparing the Efficacy and Safety of
ernakalant to Amiodarone in Recent-Onset Atrial Fibrillation
Objectives This randomized double-blind study compared the efficacy and safety of intravenous vernakalant and amioda-
rone for the acute conversion of recent-onset atrial fibrillation (AF).
Background Intravenous vernakalant has effectively converted recent-onset AF and was well tolerated in placebo-controlled studies.
Methods A total of 254 adult patients with AF (3 to 48 h duration) eligible for cardioversion were enrolled in the study. Patients
received either a 10-min infusion of vernakalant (3 mg/kg) followed by a 15-min observation period and a second
10-min infusion (2 mg/kg) if still in AF, plus a sham amiodarone infusion, or a 60-min infusion of amiodarone (5 mg/
kg) followed by a maintenance infusion (50 mg) over an additional 60 min, plus a sham vernakalant infusion.
Results Conversion from AF to sinus rhythm within the first 90 min (primary end point) was achieved in 60 of 116
(51.7%) vernakalant patients compared with 6 of 116 (5.2%) amiodarone patients (p  0.0001). Vernakalant
resulted in rapid conversion (median time of 11 min in responders) and was associated with a higher rate of
symptom relief compared with amiodarone (53.4% of vernakalant patients reported no AF symptoms at 90 min
compared with 32.8% of amiodarone patients; p  0.0012). Serious adverse events or events leading to discon-
tinuation of study drug were uncommon. There were no cases of torsades de pointes, ventricular fibrillation, or
polymorphic or sustained ventricular tachycardia.
Conclusions Vernakalant demonstrated efficacy superior to amiodarone for acute conversion of recent-onset AF. Both ver-
nakalant and amiodarone were safe and well tolerated in this study. (A Phase III Superiority Study of Ver-
nakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation [AVRO]; NCT00668759) (J Am Coll
Cardiol 2011;57:313–21) © 2011 by the American College of Cardiology Foundationa
C
c
a
o
c
i
e
t
r
t
(
a
e
i
a
d
t
a
d
M
S
ionversion of atrial fibrillation (AF) to sinus rhythm (SR)
y pharmacologic or electrical cardioversion is appropriate
or many patients with acute symptomatic AF. Early con-
ersion to SR improves symptoms, prevents the detrimental
ffects of prolonged AF, and avoids hospitalization (1–3).
lectrical cardioversion is effective but requires sedation or
ontinuing Medical Education (CME) is available for this article. From *St. George’s
niversity of London, London, United Kingdom; †Clinica di Cardiologia Università
olitecnica delle Marche, Ancona, Italy; ‡J.W. Goethe University, Frankfurt,
ermany; §University of Copenhagen, Hellerup, Denmark; University Medical
enter Groningen, University of Groningen, Groningen, the Netherlands; ¶Inter-
niversity Cardiology Institute Netherlands, Utrecht, the Netherlands; and the
Cardiome Pharma Corp., Vancouver, British Columbia, Canada. A complete list of
he institutions where the work was performed is available in the Online Appendix.
his research was supported by Cardiome Pharma Corp. (Vancouver, British
olumbia, Canada). Dr. Camm has received consulting fees from Sanofi-Aventis,
ardiome Pharma Corp., ARYx, Bristol-Myers Squibb, Pfizer, Boehringer In-
elheim, Astellas, and Merck; research grants from Daiichi, Sanofi-Aventis, Servier,
ristol-Myers Squibb, and Pfizer; and lecture fees from Sanofi-Aventis, St. Jude
edical, Medtronic, Boston Scientific, Boehringer Ingelheim, and Bristol-Myers
quibb. Dr. Capucci has received consulting fees from Merck and Sanofi-Aventis and
ecture fees from St. Jude Medical and Boston Scientific. Dr. Hohnloser has received
onsulting fees from Sanofi-Aventis, Cardiome Pharma Corp., ARYx, Bristol-Myers
quibb, Merck Sharp & Dohme, and Boehringer Ingelheim; research grants from
anofi-Aventis and St. Jude Medical; and lecture fees from Sanofi-Aventis, St. Jude
edical, Boehringer Ingelheim, Merck Sharp & Dohme, and Bristol-Myers Squibb.
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nd steering committee of, and provided lectures at symposia sponsored by Sanofi-
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onsulting fees from Boehringer Ingelheim, Cardiome Pharma Corp., and Sanofi-
ventis; and research grants from Medtronic, Biotronik, St. Jude Medical, and
straZeneca. Drs. Mangal and Beatch are full-time employees of and own stock in
ardiome Pharma Corp. All other authors have reported that they have no
elationships to disclose.p
Manuscript received March 22, 2010; revised manuscript received June 22, 2010,
ccepted July 19, 2010.nesthesia, and patients must be in a fasting state (2,4,5).
urrently available antiarrhythmic agents for pharmacologic
ardioversion of AF are limited by their delayed onset of
ction, slow metabolism, and proarrhythmic side effects, all
f which may prolong hospitalization (1,4,6,7).
See page 322
A need has been recognized for a rapidly acting, effica-
ious, and well-tolerated antiarrhythmic drug. Vernakalant
s a novel antiarrhythmic agent that shows preferential
ffects for atrial tissue and has limited actions on ventricular
issue (8,9). Intravenous vernakalant effectively converted
ecent-onset AF (lasting 3 h to 7 days) and was well
olerated in placebo-controlled phase II and III clinical trials
10–12). Conversion with vernakalant was achieved quickly,
nd the half-life of vernakalant is short (11), allowing for
arly hospital discharge.
Currently one of the most widely used agents for conversion
s the class III antiarrhythmic amiodarone, despite not being
pproved for that use in most regions (13,14). This study was
esigned to demonstrate the superiority of vernakalant injec-
ion over amiodarone injection in the acute conversion of AF
nd to assess the safety of vernakalant compared with amio-
arone in patients with recent-onset AF.
ethods
tudy design. This was a phase III, multicenter, random-
zed, double-blind, double-dummy, active-controlled study
erformed in compliance with the guidelines for good
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January 18, 2011:313–21 Vernakalant Versus Amiodarone for AF Conversionlinical practice and the Declaration of Helsinki. The
rotocol and amendments were reviewed and approved by
n institutional review board or ethics committee at each
ite, and written informed consent was obtained from
atients prior to enrollment in the study.
election of study participants. Eligible patients were
en and women between 18 and 85 years with symptomatic
ecent-onset AF (duration of 3 to 48 h) who were eligible
or cardioversion, hemodynamically stable (systolic blood
ressure 100 but 160 mm Hg and diastolic blood
ressure95 mm Hg), and taking adequate anticoagulation
herapy (if recommended by American College of Cardiol-
gy/American Heart Association/European Society of Car-
iology guidelines [4]).
Patients were excluded if they had an uncorrected QT
nterval 440 ms; familial long QT syndrome; previous
orsades de pointes (TdP), ventricular fibrillation, or sustained
entricular tachycardia (VT); symptomatic bradycardia, known
ick sinus syndrome, or ventricular rate 50 beats/min; or
RS interval 140 ms. Patients with a pacemaker; atrial
utter (AFL); atrial thrombus; unstable congestive heart fail-
re, New York Heart Association functional class IV heart
ailure, or heart failure requiring inotropes; myocardial infarc-
ion, acute coronary syndrome, or cardiac surgery within 30
ays prior to enrollment; cerebrovascular accident within 3
onths prior to enrollment; atrioventricular block; valvular
tenosis, hypertrophic obstructive cardiomyopathy, restrictive
ardiomyopathy, or constrictive pericarditis; or end-stage dis-
ase states were also excluded from the study. Other exclusion
riteria were previously failed electrical cardioversion, second-
ry causes of AF, uncorrected electrolyte imbalance, digoxin
oxicity, contraindications to amiodarone, or previous exposure
o vernakalant.
tudy interventions. Patients randomized to vernakalant
eceived a 10-min infusion of 3 mg/kg vernakalant in one
nfusion line, followed by a 15-min observation period and an
dditional 10-min infusion of 2 mg/kg vernakalant if still in
F. To maintain blinding, a 60-min infusion of placebo (5%
extrose in water) was administered in a second infusion line
ollowed by a maintenance infusion of placebo for an additional
0 min. Patients randomized to amiodarone received a 60-min
nfusion of 5 mg/kg amiodarone in one infusion line, followed
y a maintenance infusion of 50 mg amiodarone over an
dditional 60 min (equivalent to approximately 15 mg/kg over
4 h). To maintain blinding, these patients received a 10-min
nfusion of placebo (normal saline) in a second infusion line,
ollowed by a 15-min observation period and a second 10-min
nfusion of placebo if still in AF.
Both infusion lines were permanently stopped if any of
he following was observed: QTc 550 ms or QRS 180
s; symptomatic bradycardia or heart rate 40 beats/min;
ymptomatic hypotension or systolic blood pressure 85
m Hg; new bundle branch block; asymptomatic VT
asting10 consecutive beats, symptomatic VT, or any TdP
r ventricular fibrillation; one or more sinus pauses of 5 s
r complete heart block; or intolerable side effects. tPatients were not permitted to
eceive class I or III antiarrhythmic
rugs from 24 h pre-dose to 24 h
fter the start of infusion and intra-
enous or oral amiodarone within 30
r 90 days pre-dose, respectively.
lectrical cardioversion or rate con-
rol medications were permitted 2 h
fter the start of study drug infusion
f the patient was still in AF. Pa-
ients remained in the clinic facility
or at least 6 h post-dose and at-
ended a follow-up visit 7 ( 2) days
fter treatment and received a
ollow-up telephone call at 30 ( 3)
ays.
fficacy and safety analyses. The primary efficacy end
oint in this study was the proportion of patients with
onversion of AF to SR within 90 min of first exposure to
tudy drug and for a minimum duration of 1 min. All
2-lead electrocardiograms (ECGs) were adjudicated by a
linical events committee, blinded to treatment allocation.
Secondary efficacy end points included the time to conver-
ion of AF to SR within the first 90 min after the start of
nfusion, proportion of patients exhibiting no AF symptoms at
0 min, and the change in EQ-5D quality of life assessment
isual analog scale (VAS) (15) from screening to hour 2.
Exploratory efficacy end points included the time to
onversion within the first 240 min after the start of
nfusion, proportion of patients who met the primary end
oint and maintained SR with no AF relapse at hour 4, and
roportion of patients ready for discharge at 2 h.
Safety was assessed at regular intervals during the study
hrough the monitoring of adverse events (AEs), vital signs,
2-lead ECG intervals, and clinical laboratory parameters.
n addition, continuous telemetry monitoring was per-
ormed from baseline to discharge, and continuous 12-lead
olter monitoring was performed from 1 h pre-dose until a
inimum of 4 h post-dose. All ventricular arrhythmias were
djudicated by a ventricular events committee, blinded to
reatment allocation.
tatistical analyses. A sample size of 230 treated patients
n 115 per group) was calculated to provide 90% power to
etect a treatment effect of 20% (assuming an amiodarone
onversion rate of 25%).
The comparison of conversion rates between groups used
2-sided Cochran Mantel-Haenszel test stratified by coun-
ry. The log-rank test was used to compare the time to
onversion. The change in EQ-5D quality of life assessment
AS was modeled using a fixed-effects general linear model
ith change as the dependent variable, baseline score and
ge as covariates, treatment as a fixed effect, and a treatment
y baseline interaction. Estimates of the change from
aseline in QTcF were obtained from a repeated-measures
ixed-effect model with change as the dependent variable;
Abbreviations
and Acronyms
AE  adverse event
AF  atrial fibrillation
AFL  atrial flutter
ECG  electrocardiogram
SAE  serious adverse
event
SR  sinus rhythm
TdP  torsades de pointes
VAS  visual analog scale
VT  ventricular
tachycardiareatment, time, and rhythm status as fixed effects; baseline
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Vernakalant Versus Amiodarone for AF Conversion January 18, 2011:313–21nd term to account for the time that had elapsed between
onversion to SR and the time of the ECG recording as
ovariates; and patient as a random effect. For all analyses, a
ignificance level of 0.05 was used.
esults
tudy population. From April 2008 to November 2009, a
otal of 254 patients were enrolled at 66 sites in Australia,
anada, and Europe. The 2 treatment groups were well
alanced in regards to demographic and baseline character-
stics (Table 1). Of all randomized patients, 232 (116 in
ach group) received at least 1 dose of study drug and were
ncluded in the efficacy and safety analyses (Fig. 1).
fficacy. Sixty of 116 (51.7%) vernakalant patients met the
rimary end point, compared with 6 of 116 (5.2%) amio-
arone patients (p  0.0001); relative risk 10.0 (95%
onfidence interval: 4.5 to 22.2).
Conversion from AF to SR within the first 90 min
ost-dose was significantly faster in vernakalant patients
ompared with amiodarone patients (p 0.0001) (Fig. 2A).
Demographic and Baseline CharacteristicsTable 1 Demographic and Baseline Charact
Baseline characteristics
Male, n (%)
White, n (%)
Age (yrs), mean (SD)
No previous episode of AF
1–3 previous episodes of AF
3 previous episodes of AF*
Median duration of current AF, h (25%, 75% quartiles)
AF duration 24 h, n (%)
Medical history, n (%)
Hypertension
Structural heart disease†
Ischemic heart disease
Myocardial infarction
Valvular heart disease
Heart failure
NYHA functional class I‡
NYHA functional class II‡
LADD (mm), mean (SD)
LADD 50 mm
LVEF (%), mean (SD)
LVEF 50%
Medications used within 7 days, n (%)
Any rate control§
Beta-blockers
Calcium-channel blockers
Digitalis glycosides
*Data for 1 patient in the amiodarone group are missing. †Patients m
‡Denominators are based on those who had a history of heart failu
beta-blockers (excluding sotalol) and alpha- and beta-blocking agents
and digitalis glycosides included digoxin, digitoxin, and digitalis.
AF  atrial fibrillation; LADD  left atrial diastolic dimension; LVEF  leftn the group of patients who responded to vernakalant (n 
0), the median time to conversion was 11.0 min.
All patients enrolled in this study reported at least 1 AF
ymptom at screening. The most common presenting symp-
oms were palpitations, irregular pulse, rapid heart beat,
atigue, shortness of breath, dizziness, and chest tightness/
ain. There were 62 of 116 (53.4%) vernakalant patients
ith no AF symptoms at 90 min, compared with 38 of 116
32.8%) amiodarone patients (p 0.0012); relative risk 1.63
95% confidence interval: 1.20 to 2.23). Treatment with
ernakalant resulted in a significantly greater improvement
n patient perception of state of health (as measured by the
Q-5D quality-of-life assessment VAS) at hour 2 com-
ared with amiodarone. In the vernakalant group, a mean
djusted increase (from baseline) of 10.9 points was seen
ompared with a mean adjusted increase of 5.6 points in the
miodarone group (p  0.0006).
As shown in Figure 2B, a significantly greater proportion
f vernakalant patients (54.4%) converted to SR within the
rst 4 h post-dose compared with amiodarone patients
22.6%) (p  0.0001). In patients who converted to SR
cs
Treatment Group
Total
(n  232)
ernakalant
(n  116)
Amiodarone
(n  116)
5 (64.7) 71 (61.2) 146 (62.9)
1 (95.7) 111 (95.7) 222 (95.7)
.1 (10.81) 62.2 (11.63) 62.7 (11.21)
4 (29.3) 33 (28.4) 67 (28.9)
4 (37.9) 40 (34.5) 84 (36.2)
8 (32.8) 42 (36.2) 80 (34.5)
.7 (9.1, 28.7) 17.9 (9.7, 31.4) 17.7 (9.3, 30.4)
3 (62.9) 65 (56.0) 138 (59.5)
6 (74.1) 80 (69.0) 166 (71.6)
6 (31.0) 45 (38.8) 81 (34.9)
2 (19.0) 30 (25.9) 52 (22.4)
1 (9.5) 8 (6.9) 19 (8.2)
4 (3.4) 12 (10.3) 16 (6.9)
0 (17.2) 26 (22.4) 46 (19.8)
9 (45.0) 12 (46.2) 21 (45.7)
1 (55.0) 14 (53.8) 25 (54.3)
.6 (6.77) 41.0 (6.04) 40.8 (6.40)
5 (4.3) 7 (6.0) 12 (5.2)
.6 (7.34) 59.5 (6.97) 58.5 (7.21)
5 (12.9) 4 (3.4) 19 (8.2)
1 (61.2) 78 (67.2) 149 (64.2)
3 (54.3) 76 (65.5) 139 (59.9)
0 (8.6) 4 (3.4) 14 (6.0)
6 (5.2) 10 (8.6) 16 (6.9)
had 1 condition listed under the structural heart disease category.
ta-blockers included intravenous or oral nonselective and selective
rvedilol); calcium-channel blockers included diltiazem and verapamil;eristi
V
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(e.g., caventricular ejection fraction; NYHA  New York Heart Association.
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January 18, 2011:313–21 Vernakalant Versus Amiodarone for AF Conversionithin 90 min, SR was maintained through 4 h for 59 of 60
98.3%) vernakalant patients and 6 of 6 (100%) amiodarone
atients. According to the investigator, 37.1% (43 of 116) of
ernakalant patients and 9.5% (11 of 116) of amiodarone
atients were ready for discharge at 2 h (p  0.0001).
afety. Table 2 outlines the incidence of treatment-emergent
Es, serious adverse events (SAEs), and discontinuations
ecause of AEs within 24 h post-dose. There was 1 death in
his study, due to chronic obstructive pulmonary disease
xacerbation and pulmonary embolism, which occurred 24
ays after vernakalant administration. There was an SAE of
onomorphic unsustained VT in the vernakalant group, not
ssociated with QT prolongation, which began 10 min after
he start of infusion and resolved spontaneously. An SAE of
ardiac arrest, consisting of asystole with a loss of conscious-
ess, occurred in the amiodarone group 37 min after the start
f infusion and resolved after cardiac massage and atropine
ere administered. Within 2 to 24 h post-dose, there were
AEs of atrial thrombosis and syncope (related to pulmonary
mbolism) in the vernakalant group and sinus bradycardia in
he amiodarone group, all of which were considered to be
erious owing to prolongation of hospitalization and were not
elated to study drug. There were no cases of TdP, ventricular
brillation, or polymorphic or sustained VT in either group.
There was a higher incidence of AFL in vernakalant patients
8.6%) compared with amiodarone patients (0.9%) within 4 h
ost-dose. Of the 10 vernakalant patients who developed AFL,
spontaneously converted and 4 were electrically cardioverted
o SR within 4 h, and 1 patient spontaneously converted to SR
ithin 24 h. No AFL events were considered to be serious, and
one of the patients who developed AFL had 1:1 atrioventric-
Figure 1 Disposition of Patients
*One vernakalant patient did not complete the study because of death owing to c
and pulmonary embolism on day 24. SR  sinus rhythm.lar conduction during the AFL episodes. rHeart rate decreased over time in both groups; however,
n vernakalant patients, the decrease was primarily due to
onversion, and the decrease appeared to be independent of
onversion in amiodarone patients (Fig. 3). In the ver-
akalant group, QTcF transiently increased with infusion,
hereas in the amiodarone group, QTcF progressively
ncreased throughout the 4-h observation period (Fig. 4).
iscussion
his study shows that vernakalant provides a safe and
ffective alternative to amiodarone for the acute conversion
f recent-onset AF. Conversion with vernakalant was rapid
nd significantly more effective than amiodarone (52% vs.
% within 90 min). Patients treated with vernakalant had
ignificantly greater symptom relief at 90 min and a greater
erceived feeling of well-being at 2 h.
The low conversion rate in the amiodarone group may be
ttributed to the characteristics of the AF population
nrolled in this trial. A previous study (3) in AF of 48 h
ith a similar dosing regimen suggested that a conversion
ate of approximately 20% to 25% would be expected in the
miodarone group within 90 min post-infusion. However,
he AVRO study population was older, with greater comor-
idities (i.e., structural heart disease and hypertension), and
ad a longer duration of AF. In other studies, successful
ardioversion with amiodarone took several hours and
equired infusions up to 24 h (16,17).
The rapid time to conversion in vernakalant-treated
atients is consistent with previous phase III studies of
ntravenous vernakalant in patients with AF (10,11). The
enefits of early cardioversion include a reduction in the
obstructive pulmonary diseasehronicisk of recurrent AF, less need for long-term anticoagu-
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Vernakalant Versus Amiodarone for AF Conversion January 18, 2011:313–21ation or electrical cardioversion, and avoidance of
engthy and costly hospital admissions (2,5,18). Accord-
ng to their physicians, a greater proportion of ver-
akalant patients could be safely discharged home at 2 h
o resume normal activities.
Vernakalant had a significantly greater proportion of
atients with no symptoms at 90 min compared with
miodarone. Amiodarone did, however, slow heart rate
ithin the first 90 min, which may have provided
ymptom relief in some of the amiodarone patients,
Figure 2 Time to Treatment-Induced Conversion
Time to treatment-induced conversion from atrial fibrillation (AF) to sinus rhythm (S
Patients who had electrical cardioversion attempted were censored at the time ofncluding those who did not convert to SR. aThe use of available antiarrhythmic agents is limited
ecause of their delayed onset of action and increased
roarrhythmic risk. In recent-onset AF, intravenous
ropafenone converted 23% to 28% of patients within 60
in, with a mean time to conversion of 2 h (19,20), and
ntravenous flecainide converted 56% of patients within 90
in (21). However, because of their proarrhythmic poten-
ial, these class IC antiarrhythmics are contraindicated in
atients with AF with structural heart disease (4,16).
butilide, a class III antiarrhythmic with a rapid onset of
hin (A) 90 and (B) 240 min post-dose.
cal cardioversion.R) wit
electriction, has shown conversion rates within 90 min of 28% to
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January 18, 2011:313–21 Vernakalant Versus Amiodarone for AF Conversion1% compared with placebo (22,23) and 44% to 51%
ompared with other antiarrhythmic agents (24,25), with
igher efficacy in patients with AFL. Although ibutilide is
pproved in the U.S., the risk of TdP (3.6% to 8.3%) is a
oncern with its use (5), and this drug is not available in
any European countries.
Amiodarone was selected as a comparator in this study
ecause it is one of the most commonly used antiarrhythmic
gents for the conversion of AF, can be used in a broad AF
opulation, and was available in all participating countries in
his study. Although class IC agents, such as flecainide, are
ometimes the first choice for conversion of AF in many
uropean countries, they were not chosen as comparators in
his study because the intravenous formulations are not avail-
Summary of AEs Occurring Within 24 h Post-DoTable 2 Summary of AEs Occurring Within 2
0
Vernaka
(n  1
Any treatment-emergent AE* 32 (27
Any related treatment-emergent AE 22 (19
Common related treatment-emergent AEs†
Dysgeusia 8 (6.9
Sneezing 4 (3.4
Cough 3 (2.6
Any treatment-emergent SAE 3 (2.6
Any related treatment-emergent SAE 3 (2.6
Discontinuations due to AEs 3 (2.6
Values are patients, n (%). *Treatment-emergent AEs were defined a
†Common related treatment-emergent AEs were those that occurred in
2 to 24 h post-dose included bradycardia, supraventricular tachyc
vernakalant group, and increased blood bilirubin in the amiodarone g
AE  adverse event; SAE  serious adverse event.
Figure 3 Mean Heart Rate for Patients in AF and for Patients i
There was 1 patient in SR in the amiodarone group who had a heart rate of 42 beble in all countries and they are contraindicated in patients
ith AF with structural heart disease.
afety considerations. Both vernakalant and amiodarone
ere well tolerated in this study population, which included
lder patients (75 years) and those with structural heart
isease. Although there was a higher incidence of AEs in
ernakalant patients, dysgeusia (altered taste) was the most
ommon event, as observed in previous trials (10,11). The rate
f SAEs and discontinuations owing to AEs was low in both
roups, and there were no drug-related deaths.
Vernakalant and amiodarone have both been shown
reviously to cause hypotension. Accordingly, patients in
his study were adequately hydrated and hemodynamically
ptimized before receiving treatment. The incidence of
ost-Dose
Post-Dose 2–24 h Post-Dose
Amiodarone
(n  116)
Vernakalant
(n  116)
Amiodarone
(n  116)
10 (8.6) 21 (18.1) 15 (12.9)
1 (0.9) 4 (3.4)‡ 1 (0.9)‡
0 0 0
0 0 0
0 0 0
1 (0.9) 2 (1.7) 1 (0.9)
1 (0.9) 0 0
1 (0.9) 0 0
E that began or worsened following the start of study drug infusion.
tients in the study. ‡Related treatment-emergent AEs occurring within
rolonged electrocardiogram QT, and decreased heart rate in the
Over 4 h Post-Dose
in (bpm) at 10 min post-dose. Abbreviations as in Figure 2.se4 h P
–2 h
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xperience with vernakalant (11) and amiodarone (17).
In vernakalant patients, transient increases in QTcF
ccurred during infusion, whereas in amiodarone pa-
ients, QTcF progressively increased throughout the 4-h
bservation period. Decreases in heart rate in the ver-
akalant group were associated with conversion to SR,
hereas amiodarone showed decreases in heart rate that
ppeared to be independent of conversion, reflecting its
ate control properties (4,13).
tudy limitations. A limitation of this study was the short
Figure 4 Mean QTcF Interval and Mean Change From Baseline
(A) Mean QT interval corrected for heart rate using Fridericia’s formula. (B) Mean
ment group, time by treatment group interaction, and rhythm (SR vs. not SR) as fix
patient as a random effect. Values shown are the estimated adjusted mean and 9ollow-up period for efficacy (90 min) and the short infusion teriod (i.e., 24 h) for amiodarone. The 90-min efficacy
valuation period was chosen because it is consistent with
receding phase III studies of vernakalant injection (10,11). A
hort observation period before patients could proceed to
lectrical cardioversion was used because the aim of this study
as to examine the advantages of vernakalant compared with
urrent therapy. The choice of the dosing regimen for amio-
arone was based on the United Kingdom Summary of
roduct Characteristics (26). Although amiodarone was not
dministered over 24 h, the dosing regimen used in this study
roduced the expected pharmacologic effects and was similar to
4 h Post-Dose
e from baseline. Estimates are based on a mixed-effects model with time, treat-
ects; baseline and elapsed time post-conversion to SR as covariates; and
nfidence interval for patients not in SR. Abbreviations as in Figure 1.Over
chang
ed eff
5% cohat used in previous studies of amiodarone injection (3).
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January 18, 2011:313–21 Vernakalant Versus Amiodarone for AF Conversiononclusions
his study demonstrated that vernakalant infusion was supe-
ior to amiodarone infusion for the conversion of recent-onset
F, and the efficacy results were consistent with previous
tudies of intravenous vernakalant. Both vernakalant and ami-
darone were safe and well tolerated. Vernakalant has low
roarrhythmic potential and provides a rapidly acting thera-
eutic alternative for the conversion of AF.
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